Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 28;9(8):2422.
doi: 10.3390/jcm9082422.

The Impact of Korean Medicine Treatment on the Incidence of Parkinson's Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea

Hyeonseok Noh  1 , Jeongju Jang  2 , Seungwon Kwon  1   3 , Seung-Yeon Cho  1   3 , Woo-Sang Jung  1   3 , Sang-Kwan Moon  1   3 , Jung-Mi Park  1   3 , Chang-Nam Ko  1   3 , Ho Kim  4 , Seong-Uk Park  1   3
Affiliations

The Impact of Korean Medicine Treatment on the Incidence of Parkinson's Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea

Hyeonseok Noh et al. J Clin Med. .

Abstract

We aimed to investigate the association between Korean medicine (KM) treatment and the risk of Parkinson's Disease (PD) in patients with inflammatory bowel disease (IBD) in South Korea. This study analyzed data from the National Health Insurance Service-Senior cohort in South Korea. The 1816 IBD patients enrolled in the analysis comprised 411 who received only conventional treatment (monotherapy group) and 1405 who received both conventional and KM treatments (integrative therapy group). The risk of PD in patients with IBD was significantly lower in the integrative therapy group than in the monotherapy group after adjusting for confounding variables (adjusted hazard ratio (HR), 0.56; 95% confidence interval (CI) = 0.34-0.92). In the mild Charlson Comorbidity Index (CCI) group, the risk of PD in patients with IBD in the integrative therapy group was 0.39 times lower (adjusted HR, 95% CI = 0.20-0.77) than that in the monotherapy group. However, there was no significant difference in the risk of PD in patients with IBD between the integrative therapy and monotherapy groups among individuals with severe CCI (adjusted HR, 0.90; 95% CI = 0.41-1.96). IBD patients are at a decreased risk of PD when they receive integrative therapy. KM treatment may prevent PD in IBD patients.

Keywords: Korean medicine; National Health Insurance Service-Senior cohort; Parkinson’s disease; inflammatory bowel disease; nationwide population-based study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study population. CD: Crohn’s disease, IBD: Inflammatory bowel disease, ICD-10: International Classification of Diseases, 10th revision, KM: Korean medicine, PD: Parkinson’s disease, UC: Ulcerative colitis.
Figure 2
Figure 2
Kaplan–Meier survival curves for the incidence of PD in patients with IBD according to treatment (conventional [monotherapy] vs. integrated [conventional and Korean medicine]).
Figure 3
Figure 3
Kaplan–Meier survival curves for the incidence of PD in patients with IBD according to KM treatment in the mild Charlson Comorbidity Index (CCI) group (conventional [monotherapy] vs. integrated [conventional and Korean medicine]).
Figure 4
Figure 4
Kaplan–Meier survival curves for the incidence of PD in patients with IBD according to KM treatment in the severe CCI group (conventional [monotherapy] vs. integrated [conventional and Korean medicine]).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wang Q., Liu Y., Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl. Neurodegener. 2015;4:19. doi: 10.1186/s40035-015-0042-0. - DOI - PMC - PubMed
    1. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. doi: 10.1016/S1474-4422(16)30230-7. - DOI - PubMed
    1. Sheehan D., Moran C., Shanahan F. The microbiota in inflammatory bowel disease. J. Gastroenterol. 2015;50:495–507. doi: 10.1007/s00535-015-1064-1. - DOI - PubMed
    1. Houser M.C., Tansey M.G. The gut-brain axis: Is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis. 2017;3:3. doi: 10.1038/s41531-016-0002-0. - DOI - PMC - PubMed
    1. Cersosimo M.G., Benarroch E.E. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol. Dis. 2012;46:559–564. doi: 10.1016/j.nbd.2011.10.014. - DOI - PubMed

LinkOut - more resources